Jonathan Gill
Overview
Explore the profile of Jonathan Gill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
1426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Harrison D, Gill J, Roth M, Hingorani P, Zhang W, Teicher B, et al.
Pediatr Blood Cancer
. 2022 Oct;
70(1):e30017.
PMID: 36250964
Copanlisib is a pan-class I phosphoinositide 3-kinase (PI3K) inhibitor, with activity against all four PI3K class I isoforms (PI3Kα, PI3Kβ, PI3Kγ, and PI3Kδ). Whole-genome and RNA sequencing data have revealed...
12.
Jia Z, Ragoonanan D, Mahadeo K, Gill J, Gorlick R, Shpal E, et al.
Front Immunol
. 2022 Oct;
13:952231.
PMID: 36203573
Interleukin 12 (IL-12) is a naturally occurring cytokine that plays a key role in inducing antitumor immune responses, including induction of antitumor immune memory. Currently, no IL-12-based therapeutic products have...
13.
Metts J, Trucco M, Weiser D, Thompson P, Sandler E, Smith T, et al.
Cancer Med
. 2022 Sep;
12(4):4270-4281.
PMID: 36151773
Background: Patients with relapsed and refractory solid and central nervous system (CNS) tumors have poor outcomes and need novel therapeutic options. Vincristine, irinotecan, and temozolomide (VIT) is a common chemotherapy...
14.
Gill J, Gorlick R
Nat Rev Clin Oncol
. 2021 Jun;
18(10):609-624.
PMID: 34131316
Improving the survival of patients with osteosarcoma has long proved challenging, although the treatment of this disease is on the precipice of advancement. The increasing feasibility of molecular profiling together...
15.
Zvi Y, Ugur E, Batko B, Gill J, Roth M, Gorlick R, et al.
Sarcoma
. 2021 Feb;
2021:8324348.
PMID: 33603563
Background: Six cell surface receptors, human epidermal growth factor receptor-2 (Her-2), platelet-derived growth factor receptor- (PDGFR-), insulin-like growth factor-1 receptor (IGF-1R), insulin receptor (IR), c-Met, and vascular endothelial growth factor...
16.
Kinnaman M, Zhu C, Weiser D, Mohiuddin S, Hingorani P, Roth M, et al.
Sarcoma
. 2021 Jan;
2020:3498549.
PMID: 33488267
Advances in molecular diagnostics have identified subsets of Ewing and Ewing-like sarcomas driven by variant translocations with unique biology. It is likely that patients with these tumours will have different...
17.
Nevil G, Roth M, Gill J, Zhang W, Teicher B, Erickson S, et al.
Pediatr Hematol Oncol
. 2020 Aug;
38(1):8-13.
PMID: 32804009
Eltrombopag is a small molecule, thrombopoietin receptor agonist approved for the treatment of patients with aplastic anemia and chronic immune thrombocytopenia. It is also a polyvalent cation chelator and inhibits...
18.
Gill J, Zhang W, Zhang Z, Roth M, Harrison D, Rowshan S, et al.
Pediatr Blood Cancer
. 2020 Jul;
67(10):e28606.
PMID: 32706456
The pediatric preclinical testing program previously demonstrated activity of eribulin in osteosarcoma patient-derived xenograft (PDX) models. The phase 2 trial in patients with relapsed osteosarcoma failed to meet response endpoints....
19.
Cuglievan B, Berkman A, Dibaj S, Wang J, Andersen C, Livingston J, et al.
J Adolesc Young Adult Oncol
. 2020 Jul;
10(2):164-174.
PMID: 32678703
Delays in diagnosis can affect the short-term survival outcomes of adolescent and young adult (AYA) cancer patients. We sought to determine the extent to which delayed diagnosis, health insurance type,...
20.
Batth I, Dao L, Satelli A, Mitra A, Yi S, Noh H, et al.
Int J Cancer
. 2020 Jun;
147(12):3550-3559.
PMID: 32506485
Neuroblastoma (NB) is a deadly childhood disease that carries a 50% chance of relapse for anyone in remission and similar level of 5-year survival. We investigated the value of our...